Introduction: Prescription opioid (PO) abuse is a growing public health concern worldwide as evidenced by an increasing number of opioid-related hospital admissions with a striking lack of research examining the neural basis underlying cognitive symptomology. Drugs of abuse, through their impact on the dopaminergic system, are thought to disrupt the pre-frontal cognitive network regulating impulse control through performance monitoring and inhibition of goal-oriented behaviour. The objective of the present study is to examine neurocognitive processes in PO abusers (vs. healthy controls) by relying on the enhanced temporal resolution (1ms) of event-related potentials (ERPs) to track information processing abnormalities associated with cognitive control. Methods: In a naturalistic clinical study, 20 patients actively using prescription opioids and 20 healthy controls (matched for age, gender, educational level and smoking status) were assessed using a Go/NoGo paradigm, where the response to NoGo trials was evaluated. Results: Preliminary analysis reveals significantly (p<0.05) larger N200 and P300 amplitudes in patients (vs. controls) after successful NoGo trials. The N200 is a frontally distributed negative waveform reflecting the commencement of active inhibition, whereas the P300 is a fronto-centrally distributed positive waveform reflecting the termination of a previous inhibitory process. Following unsuccessful NoGo trials, error positivity (Pe) amplitudes were also significantly (p<0.05) increased in patients (vs. controls). The Pe is a fronto-central positive deflection component of the ERP representing the awareness of conscious error processing. Conclusions: These ERP results of altered cognitive control and error processing suggest the neural mechanisms underlying these cognitions are affected by chronic opioid abuse. Investigating the cognitive abnormalities experienced by PO abusers is an important factor in understanding the neural correlates of substance abuse and in predicting successful outcomes to ensure the best chance at long-term recovery for addicted individuals. Research funded by a Canadian Institute of Health Research (CIHR) grant.
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Knockdown Piccolo suppressed Methamphetamineinduced behavioral changes and dopamine release in the nucleus accumbens of mice To clarify of Piccolo in the NAc, we characterized the NAcspecific knockdown mice (mi Piccolo mice) by adeno-associated virus (AAV) vector including Piccolo miRNA. METH-induced locomotor activity of mi Piccolo mice was reduced compared with that of AAV-mock mice (Mock mice). The mi Piccolo mice suppressed the METH-induced CPP formation. In the microdialysis test, the mi Piccolo mice exhibited lower dopamine basal levels and tendency to decrease METH-potentiated dopamine release. These results suggested that Piccolo in the NAc regulates dopaminergic neuronal systems and METH-dependence related-behaviors.
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Pseudoginsenoside-F11 inhibits methamphetamine dependence by regulating GABAergic and opioidergic neuronal system in the nucleus accumbens of mice Abstract Objectives: Methamphetamine (METH) dependence is a global health and social problem, which is usually associated with serious psychiatric symptoms, and no effective therapeutic approaches have been identified. Pseudoginsenoside-F11 (PF 11 ) is an ocotillol-type saponin that is isolated from Panax quinquefolius (American ginseng). It was shown to attenuate the pharmacological effects of morphine and METH-induced neurotoxicity in mice. However, the functional roles of PF 11 in METH dependence are still unknown. In this experiment, we investigated whether PF 11 would affect METH-induced abnormal behaviors and then elucidated the mechanism of its pharmacological effects on METH responses. Results: In the conditioned place preference (CPP) test, coadministration of PF 11 and METH during the conditioning phase inhibited the development of METH-induced CPP. In addition, after developing METH-induced CPP, repeated administration of PF 11 for 5 days decreased the CPP compared with vehicletreated METH withdrawal group. In the locomotor activity test, co-administration of PF 11 and METH for 6 days attenuated METH-induced locomotor sensitization compared with administration of METH alone. Moreover, In vivo microdialysis analyses indicated that co-administration of PF 11 and METH for 7 days prevented METH-induced extracellular dopamine (DA) increase in the nucleus accumbens (NAc). Repeated PF 11 administration for 7 days increased extracellular GABA levels in the NAc, whereas single administration of PF 11 did not. Furthermore, hyperlocomotion and accumbal extracellular DA
